References: Laboratory Workflow

(1) Van Wijk, X. M. R.; Goodnough, R.; Colby, J. M. Mass spectrometry in emergency toxicology: Current state and future applications. Crit Rev Clin Lab Sci 2019, 56 (4), 225-238. DOI: 10.1080/10408363.2019.1585415  From NLM Medline.

(2) Nelson, Z. J.; Stellpflug, S. J.; Engebretsen, K. M. What Can a Urine Drug Screening Immunoassay Really Tell Us? J Pharm Pract 2016, 29 (5), 516-526. DOI: 10.1177/0897190015579611  From NLM Medline.

(3) Zhao, Y. T.; Dai, H. R.; Li, Y.; Zhang, Y. Y.; Guo, H. L.; Ding, X. S.; Hu, Y. H.; Chen, F. Comparison of LC-MS/MS and EMIT methods for the precise determination of blood sirolimus in children with vascular anomalies. Front Pharmacol 2022, 13, 925018. DOI: 10.3389/fphar.2022.925018  From NLM PubMed-not-MEDLINE.

(4) Rossi, B.; Freni, F.; Vignali, C.; Stramesi, C.; Collo, G.; Carelli, C.; Moretti, M.; Galatone, D.; Morini, L. Comparison of Two Immunoassay Screening Methods and a LC-MS/MS in Detecting Traditional and Designer Benzodiazepines in Urine. Molecules 2021, 27 (1). DOI: 10.3390/molecules27010112  From NLM Medline.

(5) Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register, 2017; Vol. 82, pp 7920-7970.

(6) Moeller, K. E.; Lee, K. C.; Kissack, J. C. Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008, 83 (1), 66-76. DOI: 10.4065/83.1.66  From NLM Medline.

(7) Hiemke, C.; Bergemann, N.; Clement, H. W.; Conca, A.; Deckert, J.; Domschke, K.; Eckermann, G.; Egberts, K.; Gerlach, M.; Greiner, C.; et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018, 51 (01/02), e1-e1. DOI: 10.1055/s-0037-1600991.

(8) Loos, G.; Van Schepdael, A.; Cabooter, D. Quantitative mass spectrometry methods for pharmaceutical analysis. Philos Trans A Math Phys Eng Sci 2016, 374 (2079). DOI: 10.1098/rsta.2015.0366  From NLM Medline.

(9) Glish, G. L.; Vachet, R. W. The basics of mass spectrometry in the twenty-first century. Nat Rev Drug Discov 2003, 2 (2), 140-150. DOI: 10.1038/nrd1011  From NLM Medline.

(10) Moeller, K. E.; Kissack, J. C.; Atayee, R. S.; Lee, K. C. Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens. Mayo Clin Proc 2017, 92 (5), 774-796. DOI: 10.1016/j.mayocp.2016.12.007  From NLM Medline.

(11) Van Eeckhaut, A.; Lanckmans, K.; Sarre, S.; Smolders, I.; Michotte, Y. Validation of bioanalytical LC-MS/MS assays: Evaluation of matrix effects. J Chromatogr B 2009, 877 (23), 2198-2207. DOI: 10.1016/j.jchromb.2009.01.003.

(12) Klepacki, J.; Davari, B.; Boulet, M.; Lizarraga, R.; Christians, U. A High-throughput HPLC-MS/MS Assay for the Detection, Quantification and Simultaneous Structural Confirmation of 136 Drugs and Metabolites in Human Urine. Ther Drug Monit 2017, 39 (5), 565-574. DOI: 10.1097/FTD.0000000000000429  From NLM Medline.

(13) Guidance for the Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine.: 2018.

(14) CLSI. Liquid Chromatography-MassSpectrometry Methods; Approved Guidline. In CLSI document C62-A, Wayne, PA: Clinical and Laboratory Standards Institute, 2014; Vol. 34.

(15) Lynch, K. L. Accreditation and Quality Assurance for Clinical Liquid Chromatography-Mass Spectrometry Laboratories. Clin Lab Med 2018, 38 (3), 515-526. DOI: 10.1016/j.cll.2018.05.002  From NLM Medline.

(16) Baselt, R. C. Disposition of toxic drugs and chemicals in man; Biomedical Publications, 1978.

(17) Vardanyan, R. S.; Hruby, V. J. Analgesics. Synthesis of Essential Drugs 2006, 19-55. DOI: Doi 10.1016/B978-044452166-8/50003-0.

(18) Liu, Y.; Lin, D.; Wu, B.; Zhou, W. Ketamine abuse potential and use disorder. Brain Res Bull 2016, 126 (Pt 1), 68-73. DOI: 10.1016/j.brainresbull.2016.05.016  From NLM Medline.

(19) Sabella, D. Antidepressant Medications. Am J Nurs 2018, 118 (9), 52-59. DOI: 10.1097/01.NAJ.0000544978.56301.f6  From NLM Medline.

(20) Church, M. K.; Maurer, M. Antihistamines. Chem Immunol Allergy 2014, 100, 302-310. DOI: 10.1159/000359963  From NLM Medline.

(21) Oh, S.; Agrawal, S.; Sabir, S.; Taylor, A. Dextromethorphan. In StatPearls, 2023.

(22) Chokhawala, K.; Stevens, L. Antipsychotic Medications. In StatPearls, 2023.

(23) Foye, W. O.; Lemke, T. L.; Williams, D. A. Foye's principles of medicinal chemistry; Lippincott Williams & Wilkins, 2008.

(24) United States. Department of Justice.; Controlled Substances Information inc.; United States. Controlled substances handbook; Controlled Substances Information, inc., 1972.

(25) Le Dare, B.; Lagente, V.; Gicquel, T. Ethanol and its metabolites: update on toxicity, benefits, and focus on immunomodulatory effects. Drug Metab Rev 2019, 51 (4), 545-561. DOI: 10.1080/03602532.2019.1679169  From NLM Medline.

(26) See, S.; Ginzburg, R. Choosing a skeletal muscle relaxant. Am Fam Physician 2008, 78 (3), 365-370.  From NLM Medline.

(27) Substance Abuse and Mental Health Services Administration. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs. Services, D. o. H. a. H., Ed.; Center for Substance Abuse Protection: 2010.

(28) Farzam, K.; Faizy, R. M.; Saadabadi, A. Stimulants. In StatPearls, 2023.

(29) Gunja, N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013, 9 (2), 155-162. DOI: 10.1007/s13181-013-0292-0  From NLM Medline.

(30) Reisfield, G. M.; Goldberger, B. A.; Pesce, A. J.; Crews, B. O.; Wilson, G. R.; Teitelbaum, S. A.; Bertholf, R. L. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. J Anal Toxicol 2011, 35 (5), 264-268. DOI: 10.1093/anatox/35.5.264  From NLM Medline.